These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28702814)

  • 1. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.
    Han SS; Erdogan SA; Toumazis I; Leung A; Plevritis SK
    Cancer Causes Control; 2017 Sep; 28(9):947-958. PubMed ID: 28702814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
    Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
    JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
    Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
    Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies.
    Han SS; Ten Haaf K; Hazelton WD; Munshi VN; Jeon J; Erdogan SA; Johanson C; McMahon PM; Meza R; Kong CY; Feuer EJ; de Koning HJ; Plevritis SK
    Int J Cancer; 2017 Jun; 140(11):2436-2443. PubMed ID: 28073150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the cancer risk management model lung cancer screening module.
    Flanagan WM; Evans WK; Fitzgerald NR; Goffin JR; Miller AB; Wolfson MC
    Health Rep; 2015 May; 26(5):11-8. PubMed ID: 25993046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.
    de Koning HJ; Meza R; Plevritis SK; ten Haaf K; Munshi VN; Jeon J; Erdogan SA; Kong CY; Han SS; van Rosmalen J; Choi SE; Pinsky PF; Berrington de Gonzalez A; Berg CD; Black WC; Tammemägi MC; Hazelton WD; Feuer EJ; McMahon PM
    Ann Intern Med; 2014 Mar; 160(5):311-20. PubMed ID: 24379002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
    Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
    Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Mar; 160(5):330-8. PubMed ID: 24378917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The United States Preventive Services Task Force recommendations for lung cancer screening.
    Blackmon SH; Feinglass SR
    Thorac Surg Clin; 2015 May; 25(2):199-203. PubMed ID: 25901563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving selection criteria for lung cancer screening. The potential role of emphysema.
    Sanchez-Salcedo P; Wilson DO; de-Torres JP; Weissfeld JL; Berto J; Campo A; Alcaide AB; Pueyo J; Bastarrika G; Seijo LM; Pajares MJ; Pio R; Montuenga LM; Zulueta JJ
    Am J Respir Crit Care Med; 2015 Apr; 191(8):924-31. PubMed ID: 25668622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose computed tomography screening for lung cancer: how strong is the evidence?
    Woolf SH; Harris RP; Campos-Outcalt D
    JAMA Intern Med; 2014 Dec; 174(12):2019-22. PubMed ID: 25317533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
    Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
    JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
    Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
    EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues with implementing a high-quality lung cancer screening program.
    Mulshine JL; D'Amico TA
    CA Cancer J Clin; 2014; 64(5):352-63. PubMed ID: 24976072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
    Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
    PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.